Results from the randomized trial showed severe oral mucositis occurred in fewer than 10% of the cases tested using the Cooral® System.

The use of the Cooral® System in lymphoma patients showed a vastly reduced risk of developing oral mucositis, and was significantly more effective when compared to the conventional method of using ice chips [Oral Mucositis Assessment Scale (OMAS) mean total 1.77 vs 3.08; p = 0.047].

As for patient reported tolerability, both diagnostic groups (myeloma and lymphoma) reported a statistically significant higher degree of tolerability when Cooral® was used as compared to ice chips [p = 0.020].